Protalix BioTherapeutics (PLX) Total Debt (2011 - 2024)

Protalix BioTherapeutics has reported Total Debt for 12 years, with the latest figure at $20.4 million in Q2 2024.

• On a quarterly basis, Total Debt changed N/A year-over-year to $20.4 million in Q2 2024; TTM through Jun 2024 was $20.4 million, a N/A change from a year earlier, with the FY2023 full-year figure at $20.3 million, changed N/A from the prior year.
• Total Debt was $20.4 million for Q2 2024 at Protalix BioTherapeutics, roughly flat from $20.4 million in the prior quarter.
• The five-year high for Total Debt was $58.5 million in Q4 2020, with the low at $3.2 million in Q3 2021.
• Average Total Debt over 4 years is $24.3 million, with a median of $20.3 million recorded in 2023.
• The sharpest annual moves came in 2020 and 2021: Total Debt surged 1260.45% in 2020, then retreated 24.69% in 2021.
• Over 4 years, Total Debt stood at $58.5 million in 2020, then plunged by 94.46% to $3.2 million in 2021, then surged by 525.22% to $20.3 million in 2023, then grew by 0.83% to $20.4 million in 2024.
• The last three Total Debt figures came in at $20.4 million (Q2 2024), $20.4 million (Q1 2024), and $20.3 million (Q4 2023), per Business Quant data.